David Page – Page 13 – Canadian Hemophilia Society

Patients’ and caregivers’ “lived experience” crucial in CHS submissions on product access
By David Page on April 7, 2020
It’s an exciting time in care for people with bleeding disorders. In recent years, a number of novel therapies have come through clinical trials and...
No emicizumab this year for non-inhibitor patients
By David Page on April 7, 2020
Montreal, April 17, 2020 – The Canadian Hemophilia Society (CHS) has learned that emicizumab (Hemlibra) will not become available for those with hemophilia A without...

Patients’ and caregivers’ “lived experience” crucial in CHS submissions on product access